Home » Merck Serono, Apitope to Collaborate on MS Drug
Merck Serono, Apitope to Collaborate on MS Drug
Apitope International NV signed an accord giving exclusive worldwide rights to Merck Serono to develop and commercialize ATX-MS-1467, a peptide therapeutic that has completed an initial clinical study in patients with multiple sclerosis, Merck Serono said.
Fox Business
Fox Business
Upcoming Events
-
23Apr
-
25Apr
-
07May
-
14May
-
30May